From Bench to Bedside: Targeting Urotensin II for Novel Hyperprolactinemia Therapies Hyperprolactinemia, a condition characterized by elevated prolactin levels in the blood, is a complex endocrine disorder with diverse etiologies and significant clinical implications. While dopamine agonists remain the mainstay of treatment, their limitations, including side effects and incomplete efficacy, necessitate the exploration of novel … Continue reading From Bench to Bedside: Targeting Urotensin II for Novel Hyperprolactinemia Therapies